| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Dayong Lee, Erin L Karschner, Garry Milman, Allan J Barnes, Robert S Goodwin, Marilyn A Huesti. Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration? Drug and alcohol dependence. vol 130. issue 1-3. 2014-01-27. PMID:23146820. |
we characterize cannabinoid disposition in oral fluid (of) after dronabinol, synthetic oral Δ(9)-tetrahydrocannabinol (thc), and sativex, a cannabis-extract oromucosal spray, and evaluate whether smoked cannabis relapse or sativex compliance can be identified with of cannabinoid monitoring. |
2014-01-27 |
2023-08-12 |
Not clear |
| M E Lync. Preclinical science regarding cannabinoids as analgesics: an overview. Pain research & management. vol 10 Suppl A. 2014-01-24. PMID:16237476. |
modern pharmacology of cannabinoids began in 1964 with the isolation and partial synthesis of delta-9-tetrahydrocannabinol, the main psycho-active agent in herbal cannabis. |
2014-01-24 |
2023-08-12 |
Not clear |
| Iain J McGilvera. Pharmacokinetics of cannabinoids. Pain research & management. vol 10 Suppl A. 2014-01-24. PMID:16237477. |
the present review focuses on the pharmacokinetics of thc, but also includes known information for cannabinol and cannabidiol, as well as the synthetic marketed cannabinoids, dronabinol (synthetic thc) and nabilone. |
2014-01-24 |
2023-08-12 |
Not clear |
| Pierre Beaulie. Toxic effects of cannabis and cannabinoids: Animal data. Pain research & management. vol 10 Suppl A. 2014-01-24. PMID:16237478. |
toxic effects of cannabis and cannabinoids: animal data. |
2014-01-24 |
2023-08-12 |
Not clear |
| Pierre Beaulie. Toxic effects of cannabis and cannabinoids: Animal data. Pain research & management. vol 10 Suppl A. 2014-01-24. PMID:16237478. |
the present article reviews the main toxic effects of cannabis and cannabinoids in animals. |
2014-01-24 |
2023-08-12 |
Not clear |
| Mark A Ware, Vivianne L Tawfi. Safety issues concerning the medical use of cannabis and cannabinoids. Pain research & management. vol 10 Suppl A. 2014-01-24. PMID:16237480. |
safety issues concerning the medical use of cannabis and cannabinoids. |
2014-01-24 |
2023-08-12 |
Not clear |
| Mark A Ware, Vivianne L Tawfi. Safety issues concerning the medical use of cannabis and cannabinoids. Pain research & management. vol 10 Suppl A. 2014-01-24. PMID:16237480. |
safety issues are a major barrier to the use of cannabis and cannabinoid medications for clinical purposes. |
2014-01-24 |
2023-08-12 |
Not clear |
| Mark A Ware, Vivianne L Tawfi. Safety issues concerning the medical use of cannabis and cannabinoids. Pain research & management. vol 10 Suppl A. 2014-01-24. PMID:16237480. |
in the present article, the evidence behind major safety issues related to cannabis use is summarized, with the aim of promoting informed dialogue between physicians and patients in whom cannabinoid therapy is being considered. |
2014-01-24 |
2023-08-12 |
Not clear |
| Douglas Gourla. Addiction and pain medicine. Pain research & management. vol 10 Suppl A. 2014-01-24. PMID:16237481. |
there is great potential for cannabinoids in the treatment of pain; however, the increasing prevalence of recreational cannabis use has led to a considerable increase in the number of people seeking treatment for cannabis use disorders. |
2014-01-24 |
2023-08-12 |
Not clear |
| Douglas Gourla. Addiction and pain medicine. Pain research & management. vol 10 Suppl A. 2014-01-24. PMID:16237481. |
evidence that cannabis abuse liability is higher than previously thought suggests that individuals with a history of substance abuse may be at an increased risk after taking cannabinoids, even for medicinal purposes. |
2014-01-24 |
2023-08-12 |
Not clear |
| Douglas Gourla. Addiction and pain medicine. Pain research & management. vol 10 Suppl A. 2014-01-24. PMID:16237481. |
smoked cannabis is significantly more reinforcing than other cannabinoid administration methods. |
2014-01-24 |
2023-08-12 |
Not clear |
| Dayong Lee, Ryan Vandrey, Damodara R Mendu, Sebastien Anizan, Garry Milman, Jeannie A Murray, Allan J Barnes, Marilyn A Huesti. Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge. Clinical chemistry. vol 59. issue 12. 2014-01-23. PMID:23938457. |
oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge. |
2014-01-23 |
2023-08-12 |
Not clear |
| Dayong Lee, Ryan Vandrey, Damodara R Mendu, Sebastien Anizan, Garry Milman, Jeannie A Murray, Allan J Barnes, Marilyn A Huesti. Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge. Clinical chemistry. vol 59. issue 12. 2014-01-23. PMID:23938457. |
oral fluid (of) cannabinoid testing, increasing in forensic and workplace settings, could be valuable for monitoring during cannabis treatment. |
2014-01-23 |
2023-08-12 |
Not clear |
| Sarah K Himes, Karl B Scheidweiler, Olof Beck, David A Gorelick, Nathalie A Desrosiers, Marilyn A Huesti. Cannabinoids in exhaled breath following controlled administration of smoked cannabis. Clinical chemistry. vol 59. issue 12. 2014-01-23. PMID:24046200. |
cannabinoids in exhaled breath following controlled administration of smoked cannabis. |
2014-01-23 |
2023-08-12 |
Not clear |
| Sarah K Himes, Karl B Scheidweiler, Olof Beck, David A Gorelick, Nathalie A Desrosiers, Marilyn A Huesti. Cannabinoids in exhaled breath following controlled administration of smoked cannabis. Clinical chemistry. vol 59. issue 12. 2014-01-23. PMID:24046200. |
Δ(9)-tetrahydrocannabinol (thc), 11-nor-9-carboxy-thc (thccooh), and cannabinol (cbn) were measured in breath following controlled cannabis smoking to characterize the time course and windows of detection of breath cannabinoids. |
2014-01-23 |
2023-08-12 |
Not clear |
| Monique Vallée, Sergio Vitiello, Luigi Bellocchio, Etienne Hébert-Chatelain, Stéphanie Monlezun, Elena Martin-Garcia, Fernando Kasanetz, Gemma L Baillie, Francesca Panin, Adeline Cathala, Valérie Roullot-Lacarrière, Sandy Fabre, Dow P Hurst, Diane L Lynch, Derek M Shore, Véronique Deroche-Gamonet, Umberto Spampinato, Jean-Michel Revest, Rafael Maldonado, Patricia H Reggio, Ruth A Ross, Giovanni Marsicano, Pier Vincenzo Piazz. Pregnenolone can protect the brain from cannabis intoxication. Science (New York, N.Y.). vol 343. issue 6166. 2014-01-23. PMID:24385629. |
the administration of the main active principle of cannabis sativa (marijuana), Δ(9)-tetrahydrocannabinol (thc), substantially increases the synthesis of pregnenolone in the brain via activation of the type-1 cannabinoid (cb1) receptor. |
2014-01-23 |
2023-08-12 |
Not clear |
| Alline C Campos, Zaira Ortega, Javier Palazuelos, Manoela V Fogaça, Daniele C Aguiar, Javier Díaz-Alonso, Silvia Ortega-Gutiérrez, Henar Vázquez-Villa, Fabricio A Moreira, Manuel Guzmán, Ismael Galve-Roperh, Francisco S Guimarãe. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. The international journal of neuropsychopharmacology. vol 16. issue 6. 2014-01-15. PMID:23298518. |
the anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. |
2014-01-15 |
2023-08-12 |
mouse |
| Zahra Shirazi-zand, Leila Ahmad-Molaei, Fereshteh Motamedi, Nima Nader. The role of potassium BK channels in anticonvulsant effect of cannabidiol in pentylenetetrazole and maximal electroshock models of seizure in mice. Epilepsy & behavior : E&B. vol 28. issue 1. 2014-01-15. PMID:23644464. |
cannabidiol is a nonpsychoactive member of phytocannabinoids that produces various pharmacological effects that are not mediated through putative cb1/cb2 cannabinoid receptors and their related effectors. |
2014-01-15 |
2023-08-12 |
mouse |
| Shusen Sun, Anthony E Zimmerman. Cannabinoid hyperemesis syndrome. Hospital pharmacy. vol 48. issue 8. 2014-01-14. PMID:24421535. |
the purpose of this review is to describe cannabinoid hyperemesis syndrome (chs), which is thought to be induced by long-term cannabis use, and provide clinical pharmacists with information to manage the hyperemetic phase of chs. |
2014-01-14 |
2023-08-12 |
Not clear |
| Thitirat Ngaotepprutaram, Barbara L F Kaplan, Norbert E Kaminsk. Impaired NFAT and NFκB activation are involved in suppression of CD40 ligand expression by Δ(9)-tetrahydrocannabinol in human CD4(+) T cells. Toxicology and applied pharmacology. vol 273. issue 1. 2014-01-06. PMID:23999542. |
we have previously reported that Δ(9)-tetrahydrocannabinol (Δ(9)-thc), the main psychoactive cannabinoid in marijuana, suppresses cd40 ligand (cd40l) expression by activated mouse cd4(+) t cells. |
2014-01-06 |
2023-08-12 |
mouse |